GENinCode inks partnership with DC's MedStar Health

The AIM-traded company said the partnership was intended to use its ‘CARDIO inCode-Score’ (CIC-SCORE) test in primary care for assessing the risk of coronary heart disease (CHD).

It explained that, by combining the results of the CIC-SCORE test with the standard American College of Cardiology Atherosclerotic Cardiovascular Disease (ASCVD) risk calculator, the collaboration was aiming to identify patients who could benefit from early preventive treatment.

The CIC-SCORE test evaluates an individual's polygenic (DNA) risk of CHD and, when combined with their clinical risk factors, provides a comprehensive assessment of CHD risk, GENinCode explained.

GENinCode said the collaboration with MedStar made it the first major US institution to begin clinical assessments of CIC-SCORE.

The board described the CIC-SCORE test as a patent-protected in-vitro diagnostic polygenic test used for assessing the risk of CHD.

GENinCode said it conducts the CIC-SCORE test at its laboratory in Irvine, California, and provides physicians with online reports through its proprietary cloud-based 'SITAB' platform.

“We are pleased to announce our first major US clinical collaboration with MedStar, which will focus on use of CIC-SCORE to identify patients at high risk of heart disease, the largest cause of death in the US,” said chief executive officer Matthew Walls.

“We look forward to working closely with the MedStar team to identify patients at risk, inform personalised treatment and prevent coronary heart disease.”

At 1008 BST, shares in GENinCode were up 3.83% at 12.2p.

Reporting by Josh White for Sharecast.com.